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Available online 26 December 2018Background: Meningioma is the most frequent primary intracranial tumour. Surgical resection remains the
main therapeutic option as pharmacological intervention is hampered by poor knowledge of their proteomic
signature. There is an urgent need to identify new therapeutic targets and biomarkers of meningioma.
Methods:We performed proteomic profiling of grade I, II and III frozenmeningioma specimens and three normal
healthy human meninges using LC-MS/MS to analyse global proteins, enriched phosphoproteins and
phosphopeptides. Differential expression and functional annotation of proteins was completed using Perseus,
IPA® and DAVID. We validated differential expression of proteins and phosphoproteins by Western blot on a
meningioma validation set and by immunohistochemistry.
Findings:Wequantified 3888 proteins and 3074 phosphoproteins across all meningioma grades and normalme-
ninges. Bioinformatics analysis revealed commonly upregulated proteins and phosphoproteins to be enriched in
Gene Ontology terms associated with RNA metabolism. Validation studies confirmed significant overexpression
of proteins such as EGFR and CKAP4 across all grades, as well as the aberrant activation of the downstream PI3K/
AKT pathway, which seems differential between grades. Further, we validated upregulation of the total and ac-
tivated phosphorylated form of the NIMA-related kinase, NEK9, involved in mitotic progression. Novel proteins
identified and validated in meningioma included the nuclear proto-oncogene SET, the splicing factor SF2/ASF
and the higher-grade specific protein, HK2, involved in cellular metabolism.
Interpretation: Overall, we generated a proteomic thesaurus of meningiomas for the identification of potential
biomarkers and therapeutic targets.
Fund: This study was supported by Brain Tumour Research.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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RNA metabolism1. Introduction
Meningiomas are the most common primary intracranial tumour
accounting for up to 36% of all primary central nervous system (CNS) tu-
mours [1]. They are classified by theWorld Health Organization (WHO)
as slow growing benign WHO grade I (~80%), atypical WHO grade II
(18%) or malignant WHO grade III (1–3%) [1]. Many meningiomas can
be treated effectively by surgical resection [2]. Excision is occasionally
associated with morbidity and can be difficult to perform dependingth Science Park, Research Way,
. Hanemann).
. This is an open access article underon tumour location, often preventing complete removal [2]. Radiother-
apy is used as an adjunct, whilst current chemotherapies remain inef-
fective [2]. Prediction of tumour recurrence and prognosis is based
primarily on histological grade and extent of surgical resection: 5 year
recurrence rates following gross total resection, for grade I, II and III me-
ningiomas are approximately 3%, 38% and 78%, respectively [2]. How-
ever, a recently described DNA methylation-based meningioma
classification may improve future predictions of tumour recurrence
and prognosis [3].
The genomic landscape of meningiomas is well characterised.
Approximately 60% sporadic meningiomas harbour mutations in the
Neurofibromatosis 2 (NF2, merlin) gene, while mutations in genes in-
cluding TRAF7, KLF4, AKT1, SMO, PIK3CA, POLR2A, PRKAR1A, AKT3 andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
There is currently no effective pharmacological intervention for
meningioma, the most frequent primary intracranial tumour.
There is now a wealth of genomic studies of meningioma that
have been pivotal in elucidating the mutational profile of these tu-
mours. However, themechanistic involvement of thesemutations
in meningioma development or their potential as therapeutic tar-
gets has not yet been established. In the molecular landscape of
meningioma, proteomics attempts to bridge the gap between the
increasing expanse of genomic, epigenomic and transcriptomic
knowledge of these tumours and the execution of these instruc-
tions at the proteome level. Previous proteomic studies have
been limited by relatively small cohorts encompassing all WHO
grades, have lacked an appropriate control or did not include tu-
mour microenvironment.
Added value of this study
In this study, we performed extensive proteomic analyses of fro-
zen tumour tissue covering all WHO grades of meningioma and
healthy human meningeal tissue as a control, including to our
knowledge, the largest sample size analysed to date of the rarest
and most therapeutically challenging, grade III meningiomas. We
did additional mutation screening of all samples and used a valida-
tion cohort. We describe the enrichment of numerous novel path-
ways including RNA processing and proteins in meningiomas, and
oncoproteins commonly upregulated among all grades. Further,
we also show upregulation of proteins including NEK9 and its ac-
tivated phosphorylated form, previously undescribed in these tu-
mours. We also demonstrate grade specific protein upregulation
and activation of proteins.
Implications of all the available evidence
This study demonstrates that proteomic and phosphoproteomic
analyses are instrumental in identifying new candidates for
targeted therapies or biomarkers of this most common brain tu-
mour. Indeed, our results confirm the significant overexpression
of several new proteins and phosphoproteins in meningioma, in-
cluding grade-specific candidates that with further investigation
may have clinical importancewhen determining an effective treat-
ment strategy.
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ningiomas [4–6]. More recently, studies have defined distinct genetic
profiles underlying primary and recurrent atypical meningioma as
well as the presence of BAP1 mutations in a subset of WHO grade III
rhabdoid meningiomas [7,8].
Potential molecular targets of meningiomas have previously been
identified including the growth factor receptors EGFR, PDGFR and
VEGFR, along with their signalling pathway activation, yet their phar-
maceutical targeting has yielded mixed results in clinical trials [9–11].
Treatment of recurrent meningioma with the EGFR inhibitors erlotinib
and gefitinib produced no significant response; whilst the VEGFR and
PDGFR inhibitor sunitinib (Sutent®), demonstrated some efficacy in re-
current/progressive high-grade meningiomas but was associated with
considerable toxicity [10,11]. Therefore, the identification of aberrantly
activated pathways and the associated molecular targets/biomarkers
remains crucial for developing novel therapeutic strategies for
meningioma.Proteomic approaches provide a powerful tool to detect differen-
tially or uniquely expressed proteins and reveal alterations in signalling
pathways. Previous studies have described differential proteomic pro-
files between meningioma grades. Okamoto et al. analysed pure popu-
lations of tumour cells, however not considering a control; whilst,
Sharma et al. analysed tumour specimens but using glial in place of
meningeal tissue as healthy control [12,13]. Most recently, Parada
et al. investigated the phosphoproteome across WHO grades of menin-
giomas and identified reduced expression of AKAP12 as a potential
prognostic marker of high-grade meningioma [14].
In this study, we present the comparative proteomic analyses of dif-
ferent WHO grades of meningiomas vs. healthy human meninges
aiming to characterise the pathogenic signature of these tumours. We
analysed the global proteome as well as enriched phosphoproteins
and phosphopeptides of 22 meningiomas and three normal meninges
and identified the differential expression of novel proteins like the
oncoproteins SET and SF2/ASF among all meningioma grades. In addi-
tion, we revealed among others, the activation of phosphoproteins like
phospho-AKT and phospho-NEK9. Grade-specific analysis allowed for
the identification of upregulated proteins and phosphoproteins and
their associated enriched biological processes in high-grade aggressive
meningiomas. We validated differential expression using additional
techniques and a validation cohort. Our results describe to our knowl-
edge, the largest proteomic study of meningioma tissue and suggest
several candidates with promise as therapeutic targets or biomarkers
in meningioma.
2. Materials and methods
2.1. Clinical material
Anonymisedmeningioma samples under the ‘J’ serieswere provided
by the BRain Archive and Information Network (BRAIN UK) under eth-
ical approval by the SouthWest research ethics committee (REC No: 14/
SC/0098; IRAS project ID: 143874, BRAIN UK Ref: 15/011). Anonymised
‘MN’meningioma samples were collected under ethical approval by the
SouthWest research ethics committee (RECNo: 14/SW/0119; IRAS pro-
ject ID: 153351) and local research and development approval (Plym-
outh Hospitals NHS Trust: R&D No: 14/P/056 and North Bristol NHS
Trust: R&D No: 3458). Clinical and histological details about the speci-
mens are presented in Supplementary Tables S1 and S2. Tumours
were separated into a ‘discovery set’ for MS analysis consisting of 22
meningiomas (WHO grade I: n = 8, WHO grade II: n = 8, WHO grade
III: n = 6) and a ‘validation set’ composed of 15 meningioma samples
(WHO grade I: n = 5, WHO grade II: n = 5, WHO grade III: n = 5).
Two frozen normal meninges were obtained from Analytical Biological
Services Inc. and one human brain cerebral meninges was purchased
from Novus Biologicals® (NB820-59183; lot B105014).
2.2. Phosphoprotein and phosphopeptide enrichment
For both phosphoprotein and phosphopeptide enrichment 2·5 mg
of protein lysate was used as starting material. Phosphoproteins were
enriched from frozen tissue using the commercially available Qiagen®
PhosphoProtein Purification Kit (Qiagen) according to the manufactur-
er's instructions. Previous studies using this kit have reported an 88%
elution recovery of phosphoproteins [15]. Protein concentration was
determined as before [16].
For phosphopeptide enrichment, samples were homogenised from
frozen in lysis buffer (8 M urea, 100 mM Tris-HCl, pH 8·0). Samples
were frozen at −80 °C for 24 h, thawed on ice and centrifuged at
16,000 ×g for 15 min at 4 °C. Supernatant was collected in Eppendorf®
Protein LoBind microcentrifuge tubes and protein concentration deter-
mined [16]. Prior to enrichment using titanium dioxide (TiO2) beads,
2·5mg of protein lysatewas subjected to in-solution digestion. Proteins
were reduced and alkylated by incubation with 0·1 M dithiotheitol
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tion with 50 mM 2-iodoacetamide in the dark for 15 min at RT. Lys-C
protease (Lysyl Endopeptidase®, Mass Spectrometry Grade, Wako)
was then added at a protease: protein ratio of 1: 100 (w/w) in 50 mM
ammonium bicarbonate (ABC) and incubated overnight (O/N) at
37 °C. Samples were diluted in 50 mM ABC to a final concentration of
2M urea and incubated O/N at 37 °Cwith trypsin (Promega,Wisconsin,
US), added at a protease: protein ratio of 1: 50 (w/w). Digested samples
were acidified to a final concentration of 0·1% trifluoroacetic acid (TFA)
and peptides desalted using HyperSep™ C18 Cartridges (Thermo Fisher
Scientific, Massachusetts, US). Columns were washed with buffer A (1%
TFA, 0·5% acetic acid), phosphopeptides eluted in buffer B (80% acetoni-
trile (ACN, LC-MS grade), 0·5% acetic acid, 1% TFA) and dried in a vac-
uum concentrator. Phosphopeptides were enriched by batch-wise
incubation with Titansphere 10 μm TiO2 beads (GL Sciences) as de-
scribed by Lasonder et al. [17]with the followingmodifications. Initially,
TiO2 beads (1 mg beads per incubation) were incubated in wash buffer
A (80% ACN, 5% TFA) followed by incubation in buffer B (60% ACN, 5%
TFA, 5% glycerol) for 5 min at 1000 rpm, RT. TiO2 beads were
sedimented by centrifugation at 2000 ×g for 1 min, buffer removed,
sample peptide digests added in 1·5ml Eppendorf® vials and incubated
with the beads under continuous shaking for 1 h. Beads were washed
three times with 100 μl buffer B, followed by three washes with 100 μl
buffer A. Phosphopeptides were eluted following a two-step elution
protocol by Fukuda et al. [18], acidified with TFA, purified by stop and
go extraction (STAGE) tips [19] and stored at−20 °C prior tomass spec-
trometry (MS) analysis.
2.3. Protein fractionation and in-gel digestion
Proteins and phosphoproteins were separated using SDS-PAGE on
4–15%Mini-PROTEAN® TGX™ Precast Gels (Bio-Rad). For global prote-
ome analysis 50 μg of protein lysate was separated. Gels were stained
with Coomassie Blue R-350 (GE Healthcare Life Sciences) until lanes
were visible. Destaining was performed using a destaining solution
(50% LC/MS grade water, 40% MeOH and 10% acetic acid) O/N at RT.
Sample lanes were excised from gels, sliced into 6 fractions that were
cut into 1 × 1 mm pieces before in-gel digestion. In-gel digestion was
performed following Shevchenko et al. [20]. Briefly, gel pieces were
equilibrated with alternate incubation of 100% acetonitrile and 50 mM
ABC. Proteins were reduced by incubation with 10 mM DTT in 50 mM
ABC for 20 min at 56 °C in shaking at 700 rpm and then alkylated by in-
cubation with 50 mM 2-iodoacetamide in 50 mM ABC for 20 min at RT
in the dark. Proteinswere digested in 12·5 ng/μl trypsin (Promega,Wis-
consin, US) in 50mMABCO/N at 37 °C. Digested peptideswere acidified
with a final concentration of 2% TFA for 20min at RT 1400 rpm. Peptides
were then extracted by two 5min incubations of gel pieceswith buffer B
(80% ACN, 0.5% acetic acid, 1% TFA) at 1400 rpm. Supernatant was
pooled together for each sample and ACN was evaporated in a vacuum
concentrator.
Digested peptides and phosphopeptideswere purified by STAGE tips
[19]. Peptides were loaded onto C18-StageTips (Empore™ SPE Disks
C18, 3 M) conditioned by 50 μl of methanol and equilibrated using 50
μl buffer B (80% ACN, 0·5% acetic acid, 1% TFA) followed by 50 μl buffer
A (1% TFA, 0·5% acetic acid). Tips were washed with 50 μl buffer A and
peptides eluted in 40 μl buffer B into LoBind microcentrifuge tubes.
Eluted peptides were dried down completely in a vacuum concentrator
and peptides resuspended in buffer A.
2.4. Liquid chromatography tandem mass spectrometry and protein
identification
MS and protein identification was carried out as previously de-
scribed [16], with the following modifications. MS data was analysed
to identify proteins with the Andromeda peptide database search en-
gine integrated into the computational proteomics platform MaxQuantversion (1.5.0.30) [21–23]. Andromeda search parameters for protein
identification specified a first search mass tolerance of 20 ppm and a
main search tolerance of 4·5 ppm for the parental peptide. Minimal
peptide length was set at six amino acids. Proteins were quantified
with label free quantification (LFQ) values representing normalised
summed peptide intensities correlating with protein abundances,
where the ‘match between run’ option was permitted between runs
with a 0·7 min elution time interval. Venn diagrams depicting the dis-
tribution of identified proteins and phosphoproteins were created
with Venny 2.1 (http://bioinfogp.cnb.csic.es/tools/venny/index.html).
2.5. Protein quantification analysis and functional annotation analysis
LFQ values were log2 transformed using the Perseus software suite
1.5.0.31 [22] to achieve normal data distribution, which was verified
by visual inspection of histogram distribution plots of log2 transformed
data generated in Perseus for each sample. Proteins identified in at least
three runs were considered for LFQ and entries with an LFQ equal to
zero were kept. Statistical significance of changes in abundance be-
tween sample groups was calculated by a two-tailed t-test, with p-
values adjusted for multiple testing by a permutation-based FDR at 5%.
Microsoft Excel was used to calculate ratios and fold changes (FC)
followed by log2 transformation. A log2 FC ≥ 1·5 and log2 FC ≤ −1·5
with adjusted p-value b 0·05 were considered. Results are visualised
by Volcano plots. Differentially expressed proteins (DEPs) for hierarchi-
cal clustering were obtained by submitting relative expression profiles
identified in at least three runs to Perseus and performing a four-
group one-way ANOVA (p-value b 0·05) on imputation supplemented
data. Venn diagrams depicting upregulated proteins and phosphopro-
teins among all meningioma grades were created using euler APE
(http://www.eulerdiagrams.org/eulerAPE/).
Pathway enrichment analysis was generated through the use of
IPA® (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/
ingenuity-pathway-analysis). Statistical significance of enriched path-
wayswas assessed by right-tailed Fisher's exact test and considered sig-
nificant for p (FET) b 0.05. GO enrichment analyses were performed
using the Database for Annotation, Visualization and Integrated Discov-
ery (DAVID) v6.8 (https://david.ncifcrf.gov/) against a background of
the H. sapiens proteome [24]. Enrichment of GO FAT terms was consid-
ered statistically significant when corrected for multiple testing by the
Benjamini-Hochberg method with adjusted p-values b 0·05. Cytoscape
plugin EnrichmentMap (http://www.cytoscape.org/) was used to visu-
alise enriched GO terms [25].
Molecular signatures for higher grademeningiomas were generated
with the GeneSign module in BubbleGUM software (https://omictools.
com/bubblegum-tool). Grade II and III samples were defined as subsets
of interest (test classes), with NMT and grade I samples as references.
The Mean (test)/ Mean method was applied for extracting molecular
signatures.
Phosphorylation siteswere classified as described byVillen et al. [26]
with the following addition: pY at position 0 then classify as “Tyrosine”.
2.6. DNA purification and genotyping
DNA purification was performed with Qiagen® DNeasy® Blood &
Tissue Kit (Qiagen) following manufacturer's instructions. DNA was
screened for NF2 mutations by the Manchester Centre for Genomic
Medicine using Next Generation sequencing (NGS) and Multiplex
Ligation-dependent Probe Amplification (MLPA®) dosage test. Muta-
tional screening of AKT1, KLF4, TRAF7, SMO, SMARCB1 and POLR2Awas
completed using KASP genotyping [27].
2.7. Cell culture and proliferation assay
The immortalised benign meningioma cell line, Ben-Men-1 (BM1)
(DSMZ Cat# ACC-599, RRID:CVCL_1959) [28] and the malignant
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cultured in meningioma medium (Dulbecco's Modified Eagle's Media
(DMEM; Thermo Fisher Scientific), supplemented with 10% foetal bo-
vine serum (FBS; Sigma-Aldrich®), 1% D-(+)-glucose (Sigma-
Aldrich®), 100 U/ml penicllin/streptomycin (Thermo Fisher Scientific)
and 2 mM L-glutamine (Thermo Fisher Scientific)) at 37 °C in humidi-
fied 5% CO2. Human meningeal cells (HMC) were obtained from
ScienCell™ and routinely cultured in themanufacturer's recommended
medium and growth supplements at 37 °C in humidified 5% CO2. BM1
and KT21 cell lines were plated in 96-well culture plates (Greiner Bio-
One; #655088) at approximately 3000 cells perwell. Cells were allowed
to adhere and proliferate for 24 h. AZD5363 and Ku-0063794
(Selleckchem.com) were resuspended in dimethyl sulfoxide (DMSO;
Sigma-Aldrich®) and serially diluted to the appropriate concentration
in meningioma medium. Vehicle-treated control cells were grown
with the addition of 0·1% DMSO. Cells were treated every 24 h by care-
ful removal of media from wells, as not to detach cells, followed by ad-
dition of fresh drug during a 72 h incubation period at 37 °C in
humidified 5% CO2. Cell viability was determined using the ‘CellTiter-
Glo® Luminescent Cell Viability Assay’ (Promega; #G7570). Each drug
concentration was tested in triplicate. Cell viability was calculated as a
percentage of control cells, untreated cells as negative control and
media alone as positive control. Graphswere generated using GraphPad
Prism 5.
2.8. Cell lysate and tumour tissue preparation
Meningioma tissue samples of the validation set were manually
homogenised from frozen in approximately 400 μl lysis buffer
consisting of RIPA buffer (50 mM Tris-HCl pH 7.4, 0·1% SDS, 1% NP-40,
150 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 0·5% so-
diumdeoxycholate) protease inhibitor used at 1:20 (cOmplete™, EDTA-
free Protease Inhibitor Cocktail, Sigma-Aldrich®; #11873580001) and
phosphatase inhibitor cocktails used at 1:100 (Santa Cruz Biotechnol-
ogy, Inc.; sc-45,045; sc-45,065). Cells were similarly lysed in a volume
of lysis buffer appropriate for the size of cell culture dish. Lysates were
placed at−80 °C for at least 24 h before being thawed on ice and centri-
fuged at 16,000 ×g for 15 min at 4 °C. Supernatant was transferred to
fresh 1·5 ml microcentrifuge tubes and protein concentration deter-
mined as before using the Pierce™ BCA Protein Assay Kit.
2.9. Western blotting
Proteins were separated on 8% or 15% Laemmli SDS-PAGE, depend-
ing upon themolecular weight of the protein of interest and transferred
to a polyvinylidene difluoride membrane (Immun-Blot® PVDF mem-
brane, Bio-Rad). Membranes were blocked for 1 h at room temperature
with 5% skimmed milk in phosphate buffered saline (PBS) with 0·05%
Tween-20, before incubation with specific primary antibodies O/N at
4 °C. Primary antibody details are listed in Supplementary Table S3. Spe-
cific antigen-antibody interaction was detected with anti-mouse and
anti-rabbit secondary antibodies conjugated to horseradish peroxidise
(Bio-Rad). Detection was achieved using the ECL or ECL Plus Western
Blotting substrate (Pierce). Membranes were exposed to Amersham
Hyperfilm ECL (GE Healthcare Life Sciences). Films were scanned at a
resolution of 600 dpi using a HP Scanjet 2400.
2.10. Immunohistochemistry
Four-micrometer paraffin sections were de-waxed, rehydrated and
incubated with primary antibodies at room temperature O/N using an-
tigen retrieval methods as previously described [9]. Primary antibody
details are listed in Supplementary Table S3. Proteins were visualised
with the Vectastain Universal Elite ABC kit (Vector Laboratories Ltd).
Slides were counterstained with haematoxylin (Sigma-Aldrich). As a
control, sectionswere incubatedwith omission of the primary antibody.Immunohistochemical results were reviewed by neuropathologist, Hil-
ton, DA. Semi-quantitative assessment of staining intensity was scored
as follows: 0 if negative; 1 if low immunoreactivity; 2 if moderate and
3 if high.
2.11. Data availability
Proteomics data have been deposited to the ProteomeXchange Con-
sortiumvia the PRIDEpartner repository [30]with the following dataset
identifiers and reviewer account details: global proteome PXD007073;
phosphoproteome PXD007044; phosphopeptides PXD007125.
3. Results
3.1. Mutational screening of meningioma
To determine the presence of NF2mutations in the discovery set we
performed NGS and MLPA. In all but five tumours, we confirmedmuta-
tions in the NF2 gene; we further screened the remaining five for hot-
spot mutations in AKT1, KLF4, TRAF7, SMO, SMARCB1 and POLR2A [4,5]
using KASP, but we did not identify any mutation (Supplementary
Table S4). We additionally used Western blotting to determine the ex-
pression of NF2 and pNF2-S518. In general, all 22 tumour lysates
showed some expression of NF2 protein except for the grade III sample,
J17 (Supplementary Fig. S1a). This finding may be seen to conflict with
the NF2−/− genotype confirmed by NGS and MLPA of some tumours.
However, it is likely NF2 expression originates from the tumour micro-
environment. Indeed, meningiomas are described as heterogeneous tu-
mours comprising mainly of tumour cells alongside a variable presence
of infiltrating immune cells, most frequentlymacrophages [31]. Further,
expression of pNF2-S518 could not be detected in any NF2−/− con-
firmed tumours and thus may be the better complementary technique
in addition to mutational screening (Supplementary Fig. S1a). In con-
trast, four of the five NF2+/+ meningiomas could clearly be seen to
show higher NF2 expression with concomitant pNF2-S518 expression
(J8, J15, J1 and J2) compared to all other tumours and NMT inWB (Sup-
plementary Fig. S1a).
3.2. Proteins identified in meningiomas
We performed in-depth global protein and phosphoprotein expres-
sion profiling of human meningiomas compared to normal human me-
ninges. We analysed a total of 22 meningiomas; global proteome and
phosphoprotein pull-down was performed on 14 meningiomas, whilst
global proteome and phosphopeptide analysis was performed on the
remaining 8 samples. Phosphoprotein and phosphopeptide analyses re-
quired large quantities of starting material and thus were mutually ex-
clusive for tumour samples. In total, we sequenced and identified 3905
proteins and 3162 phosphoproteins with 1% FDR (Supplementary
Table S5). We identified 3619 proteins within NMT, 3850 across grade
I, 3852 across grade II and 3855 across grade III (Supplementary
Fig. S2a). From the phosphoprotein dataset we identified 2793 phos-
phoproteins in NMT, 2965 across grade I, 2934 across grade II and
2868 across grade III (Supplementary Fig. S2b).
3.3. Commonly upregulated proteins and phosphoproteins among all
meningioma grades
Proteins and phosphoproteins identified in at least 3 runs were
quantified by LFQ and transformed into relative expression data across
all grades resulting in expression profiles for 3888 proteins (Supple-
mentary Table S6a) and 3074 phosphoproteins (Supplementary
Table S6b). To get an overview we first grouped meningioma samples
by hierarchical clustering based on differentially expressed proteins
(DEPs) across all grades and healthy controls (Fig. 1a and b). Global pro-
teome revealed a clear separation of tumour from control based on
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grades, with the exception of the grade III sample J9, which was
assigned to the grade II cluster (Fig. 1a). Three clusters of proteins
displayed higher expression in at least one grade compared to NMT.
The cluster having higher expression across all grades included EGFR,
PRKDC, XRCC5, TOP1, TOP2B, SON and the DEAD box RNA helicases
DDX5, DDX6, DDX17 and DDX42; whilst two smaller clusters with in-
creased grade III-specific expression contained mainly mitochondrial
related proteins (Fig. 1a). Similarly, the phosphoprotein dataset showed
a marked separation of tumours vs. control, with meningiomas cluster-
ing into respectiveWHOgrade (Fig. 1b). Again,we identified threemain
clusters of phosphoproteins displaying higher expression in at least one
grade compared to NMT. Among phosphoproteins present in the largest
cluster were AKT1 and 2, NEK7, NEK9, PDGFRB, NFKB1, MAPK2 and
mTOR. The grade III-specific cluster contained the serine/threonine pro-
tein kinase ATR, theminichromosomemaintenance proteinsMCM3 and
MCM6, previously identified in meningioma cell lines [32], and the
DEAD box RNA helicases DDX10 and DDX24 (Fig. 1b).
Next, we focussed on proteins and phosphoproteins upregulated in
meningiomas compared to control, enabling us to identify
overexpressed proteins and differences in protein phosphorylation sta-
tus. We determined significantly upregulated proteins and phospho-
proteins common to all meningioma grades by overlapping
upregulated DEPs from all grades, as depicted in the Venn diagrams
(Fig. 1c and d; Supplementary Table S6). This enabled us to identify
181 proteins and 338 phosphoproteins to be commonly upregulated
among all grades vs. NMT, some not yet described in meningiomas in-
cluding SET, TRIP6 and the copper transport protein ATOX1. Partial
lists of significantly upregulated proteins and phosphoproteins com-
mon to all grades are shown in Tables 1 and 2 respectively.
3.4. Functional annotation of commonly upregulated proteins and phos-
phoproteins in meningiomas
Functional annotation analyses were performed to establish signal-
ling pathways, biological processes and molecular functions associated
with DEPs. We annotated the 181 proteins and 338 phosphoproteins
upregulated among all grades by GO enrichment analysis (Supplemen-
tary Table S7a and b), and compared significantly enriched terms of
phosphoproteins with corresponding fold enrichments of proteins to
identify GO terms predominantly targeted by phosphorylation. The
most relevant enriched GO terms are presented in Fig. 2a; among the
most upregulated proteins were RNA helicase activity (23-fold), COPI
vesicle coat (51-fold) and the RNA export from nucleus (9-fold) in the
‘molecular function’, ‘cellular components’ and ‘biological process’
groups respectively. Several terms with the strongest enrichment for
phosphoproteins were found associated with RNA helicase activity
(17-fold) and COPI vesicle coat (16-fold), but we also identified specific
phosphoprotein-enriched terms including the signal complex assembly
(33-fold), EGFR (6-fold) and VEGFR (6-fold) signalling pathways, the
last two already described in meningiomas [9–11] (Fig. 2a).
To obtain a global view of the biological functions associated with
upregulated proteins and phosphoproteins, enriched GO terms were
visualised in an ‘enrichment map’ (Fig. 2b and c; Supplementary
Table S7c and d). Six clusters of GO terms were identified in the protein
enrichment map, the largest comprised of 36 nodes associated with
transcription/post-transcriptional modifications, including nodes re-
lated to mRNA processing and the spliceosomal complex, which was
also identified in two additional clusters (‘splicing machinery’ and
‘spliceosomal complex’) (Fig. 2b). The phosphoprotein enrichment
map displayed five clusters of GO terms representing biological func-
tions; the most represented were ‘transcription/pre mRNA processing’
and ‘signal transduction’, with 34 and 21 nodes respectively (Fig. 2c).
Finally, we used IPA to identify canonical pathways significantly as-
sociated with upregulated proteins and phosphoproteins. IPA revealed
22 and 198 pathways associated with proteins and phosphoproteins,respectively (Supplementary Table S7e and f). Pathways containing ≥2
proteins or phosphoproteins were grouped under broader functional
pathway classes according to Ingenuity Canonical Pathways (Fig. 2d).
Classes associated with upregulated proteins included ‘cellular immune
response’ and ‘intracellular and second messenger signaling’, with no
more than four pathways in a class at any time. Upregulated phospho-
proteinsweremost frequently associatedwith pathways related to ‘cel-
lular growth, proliferation and development’, ‘cellular immune
response’, ‘disease-specific pathways’, ‘cancer’ aswell as ‘transcriptional
regulation’; within these groups we identified the integrin, EIF2, FAK,
ERK/MAPK, paxillin, Rho Family GTPases and G-protein coupled recep-
tor signalling pathways (Supplementary Table S7f).
3.5. Differential protein and phosphoprotein expression between meningi-
oma grades
Next, we performed comparative analysis to identify DEPs between
grades. Significant differences were assessed by Student's t-tests and
DEPs visualised in Volcano plots (Fig. 3; Supplementary Table S8). We
identified 260 proteins to be significantly differentially expressed be-
tween grade II vs. grade I (Fig. 3a), 424 proteins between grade III vs.
grade I (Fig. 3b) and 243 proteins between grade III vs. grade II
(Fig. 3c). Proteins significantly upregulated in grade II meningiomas
vs. grade I included the DNA damage response proteinMRE11, TOP1 in-
volved in DNA replication and NCBP1, a component of the cap-binding
complex that binds the 5′-cap of pre-mRNAs and plays a role in RNA
biogenesis (Fig. 3a). Within higher-grade specific proteins, we identi-
fied the glycolytic enzyme HK2 (hexokinase-2), known for its key role
in aerobic glycolysis [33], and the mitochondrial related proteins
HSPE1 and IDH3B (Fig. 3b and c).
Among the phosphoproteins we found 404 DEPs between grade II
vs. grade I (Fig. 3d), 423 DEPs between grade III vs. grade I (Fig. 3e)
and 346DEPs between grade III vs. grade II (Fig. 3f). Significantly upreg-
ulated phosphoproteins in grade II meningiomas included EFNB2, a li-
gand for the EPH family of RTKs, recently identified to be activated in
NF2-deficient meningioma (Fig. 3d) [34]. Among the downregulated
phosphoproteins was the MAP kinase-specific phosphatase PTPN7, a
negative regulator of ERK2 in K562 leukaemia cells [35] (Fig. 3d).
Grade III-specific upregulated phosphoproteins included the cell cycle
checkpoint protein ATR, often critical for tumour cell survival during in-
creased levels of DNA replication stress and described as a therapeutic
target for advanced solid tumours (Fig. 3e and f) [36].
To better characterise the proteomic landscape of aggressivemenin-
giomas by considering also NMT as control, we extracted individualmo-
lecular signatures for grade II and grade III using the computational tool
BubbleGUM. A grade II signature was generated by comparison with
NMT and grade I, and a grade III signature by comparison with NMT,
grade I and grade II, keeping the FC N 2. Hierarchical clustering of rela-
tive expression of proteins and phosphoproteins revealed clustering of
tumour samples into their respective grades, again with the exception
of J9 (Fig. 3g and h). We identified grade II and III signatures of 191
and 192 proteins respectively (Fig. 3g), and grade II and III signatures
of 88 and 84 phosphoproteins respectively (Fig. 3h). Among these,
were upregulated proteins already visualised in volcano plots (Fig. 3a–
f); yet, additional grade-specific proteins were established like the
minichromosome maintenance protein MCM6 in grade II meningioma
and the grade III-specific mitochondrial proteins ATP5EP2 and SUCLG2
(Fig. 3g). Grade II-specific phosphoproteins included the tumour sup-
pressor PTEN, suggested to contribute to oncogenesis when inactivated
by phosphorylation [37] (Fig. 3h). In grade III meningiomas we identi-
fied increased expression of the RNA helicase phosphoprotein
DDX19B that upon phosphorylation by CHEK1 functions in the DNA
damage response in an ATR/CHEK1-dependent manner [38] (Fig. 3h);
indeed, ATR was identified as a grade III-specific phosphoprotein in
our previous analyses (Fig. 1b; 3e and f). Complete lists of proteins
and phosphoproteins are shown in Supplementary Tables S9a–d.
Fig. 1. Comparative analysis of the global proteome and phosphoproteins of different grades of meningiomas. (a) Unsupervised hierarchical clustering of 481 differentially expressed
proteins (meningiomas n = 22; NMT n = 3). Tumours clustered separately from NMT and into respective WHO grades, with the exception of the grade III sample, J9. Three protein
clusters are annotated demonstrating higher relative expression in at least one or more meningioma grade compared to NMT. (b) Unsupervised hierarchical clustering of 1296
differentially expressed phosphoproteins (meningiomas n = 14; NMT n = 3). Tumours clustered separately from NMT in their phosphoprotein profiles. Three phosphoprotein
clusters are annotated showing higher relative expression in at least one or more meningioma grade compared to NMT. Clustering was generated using Perseus 1.5.0.31 software
suite, based on four-group one-way ANOVA, p-valueb.05, corrected for multiple testing. (c) Venn diagram depicting unique and common upregulated proteins among different menin-
gioma grades vs. NMT. (d) Venn diagram depicting unique and common upregulated phosphoproteins among different meningioma grades vs. NMT. Upregulated: log2 FC ≥ 1.5;
p-value b .05 (two-tailed t-test). Venn diagrams were created using Euler APE (http://www.eulerdiagrams.org/eulerAPE/). Proteomic data used to create this figure are provided in Sup-
plementary Table S6a and b.
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tate the grade III-specific signature of proteins and phosphoproteins
(Fig. 3i and j; Supplementary Table S9e and f). The most enriched pro-
tein termswere acyl-CoA dehydrogenase activity (23-fold), precatalytic
spliceosome (19-fold) and tricarboxylic acid cycle (26-fold) in the three
groups respectively; overall, the majority of enriched terms were asso-
ciated with mitochondrial function (Fig. 3i). Among grade III-specific
phosphoproteins, terms with the strongest enrichments included RNA
helicase activity (65-fold), small-subunit processome (26-fold) and
RNA secondary structure unwinding (29-fold) in the three groups re-
spectively, with terms mainly linked to RNA activity and ribosome bio-
genesis (Fig. 3j).
3.6. Compendium of protein phosphorylation sites in meningiomas
In order to identify specific phosphorylation sites, we enriched and
analysed phosphorylated peptides by MS. Overall, we sequenced and
identified 3622 phosphopeptides, of which 2729 (75%) were identified
with a phosphosite post-translational modification (PTM) localization
probability score N 0.75 (Supplementary Table S10a). Our distribution
of serine (~90%), threonine (~9%) and tyrosine (~1%) phosphorylation
sites (Fig. 4a)were similar to previous studies [39].We further classified
phosphopeptides based on their chemical properties using a binary de-
cision tree [26]. The majority of sites were classified as either proline-
directed (33%) or basic (32%), followed by acidic (21%), other (13%)and tyrosine (1%) (Fig. 4b). The 3622 identified phosphopeptides cov-
ered 1320 proteins, of which 56% overlapped with the phosphoprotein
dataset. GO analysis of the overlap showed a strong enrichment in
terms related to the cellular membrane and its adhesion properties
(e.g. basal cortex, zonula adherens, podosome assembly), microtubule
regulation, cytoskeletal organization and DNA binding (Fig. 4c; Supple-
mentary Table S10b). Additionally, we analysed the 1320 proteins asso-
ciated with the enriched phosphopeptides using IPA and identified 211
significantly associated canonical pathways (Fig. 4d; Supplementary
Table S10c). Pathways were grouped under broader functional classes
as before. Proteins identified by phosphopeptides showed a similar
trend of pathway classification when compared to the identified upreg-
ulated phosphoproteins (Fig. 4d); the majority of pathways were asso-
ciated with ‘cellular growth, proliferation and development’ (34
pathways) and ‘cellular immune response’ (34 pathways).3.7. Validation of identified proteins and phosphoproteins
We validated our proteomic results with a subset of proteins and
phosphoproteins identified as upregulated in meningiomas compared
to NMT.We validated byWB on a selection of the discovery set samples
as well as on a validation set of 15 meningiomas (Fig. 5a; Supplemen-
tary Fig. S3). NF2 expression of the validation set is shown in Supple-
mentary Fig. S1b.
Fig. 2. Functional annotation of proteins and phosphoproteins significantly upregulated and common to all meningioma grades. (a) Gene Ontology (GO) enrichment analysis by theweb
tool DAVID v6.8. Terms containing at least three phosphoproteins with Benjamini-Hochberg adjusted p b .05 and corresponding enrichment for proteins is shown. Gene Ontologies
representing Molecular Function are presented in red, Cellular Component in green and Biological Processes in blue. Fold enrichment relative to the H. sapiens proteome is displayed at
the x-axis. Supplementary Table S7a and b provide details of the GO enrichment analysis and the genes involved. (b) Enrichment map of GO terms enriched in upregulated proteins
shown in an interaction network. (c) Enrichment map of GO terms enriched in upregulated phosphoproteins. Nodes represent enriched GO terms with colour intensities reflecting sta-
tistical significance and line thickness correlating to the degree of overlap. Numbers refer to descriptions provided in (a) and Supplementary Tables S7c and d. (d) Ingenuity PathwayAnal-
ysis of commonly upregulated proteins and phosphoproteins. Pathways significantly associated with two or more proteins or phosphoproteins (Fisher's exact test right-tailed, p-value
b .05) were grouped into pathway classes according to Ingenuity Canonical Pathways. Supplementary Tables S7e and f provide details of IPA pathway analysis and pathway classification.
83J. Dunn et al. / EBioMedicine 40 (2019) 77–91We confirmed the significant overexpression of EGFR, NEK9, STAT2,
EPS8L2, CKAP4 and SET in all grades compared to NMT by WB with an
average of ~15 folds for EGFR, ~6 folds for NEK9, ~10 folds for STAT2,
~4 folds for EPS8L2 ~9 folds for CKAP4 and ~16 folds for SET (Fig. 5aand b). Further, WB quantification established HK2 as statistically
overexpressed in grade II and III vs. grade I meningiomas; indeed, HK2
was identified as a higher-grade specific protein in our earlier analyses
(Fig. 5b; 3b and c). By WB, we additionally confirmed the
84 J. Dunn et al. / EBioMedicine 40 (2019) 77–91overexpression of PXN, TRIP6, S100-A10, SF2/ASF and ATOX1; all the
proteins listed above showed immunoreactivity in the majority of me-
ningiomas with weak or absent expression in NMT (Fig. 5a and b).
Among the phosphoproteins, we confirmed the overexpression of
pPXN-Y118, although variable across meningioma samples and grades,
and pNEK9-T210, which was phosphorylated across all samples and
grades with weak expression in NMT (Fig. 5a). Lastly, pAKT2-S474demonstrated variable expression in grade I and II meningiomas and
was not detected in grade III, whilst the phosphorylation of AKT1 on
S473 was detected predominantly in grade I and II meningiomas
(Fig. 5a). Total AKT1 and AKT2 were identified in all grades (Fig. 5a).
As a proof of principle we further investigated the potential of
pAKT1-S473 as a therapeutic target in low-grade meningioma in vitro
using the benign meningioma cell line, BM1, and the malignant
85J. Dunn et al. / EBioMedicine 40 (2019) 77–91meningioma cell line, KT21 [28,29]. First, we established activation of
the PI3K/AKT/mTOR pathway in the meningioma validation set by the
phosphorylation of two downstream targets, GSK3β and PRAS40
[40,41]. Expression of pGSK3β-S9 and pPRAS40-T246 followed a trend
similar to pAKT1-S473, displaying lower expression in grade III com-
pared to grade I and II meningiomas (Supplementary Fig. S4a and b).
Next, we confirmed that whilst both BM1 and KT21 showed increased
pAKT1-S473 levels compared to normal human meningeal cells
(HMC), KT21 demonstrated a significant reduction in pAKT1-S473 com-
pared to BM1 by WB (Supplementary Fig. S4c and d). Cells were then
treated with the pan-AKT kinase inhibitor, AZD5363, previously
shown to be effective in the treatment of metastatic grade I
meningothelial meningioma [42]. Treatment of BM1 and KT21 cells
with AZD5363 reduced phosphorylation of GSK3β and PRAS40 30 min
post-treatment, yet following treatmentwith increasing concentrations
of AZD5363 the IC50 of BM1 and KT21 cells were high at 33·1 μM and
67·8 μM, respectively (Supplementary Fig. S4e and f). Next, we sought
to determine if inhibition of the mTOR complex, previously described
to be activated in meningioma, may be a more promising target [43].
We selected the dual mTOR inhibitor Ku-0063794 that has demon-
strated preclinical efficacy in reducing the viability of renal cell carci-
noma cell lines [44,45]. Following treatment of BM1 and KT21 cells
with Ku-0063794, pGSK3β-S9 levels in KT21 cells decreased to less
than half that of vehicle-treated cells but not in BM1, whilst
pPRAS40-T246 displayed similar reduction in BM1 and KT21 cells
(Supplementary Fig. S4g). Following treatment of BM1 and KT21 cells
with Ku-0063794, BM1 cells showed a greater reduction in cell viability
with an IC50 of 1·1 μM,whereas KT21 cells reached IC50 at 3·6 μM, over
double that of BM1 (Supplementary Fig. S4h).
In addition to validation byWB, we performed IHC studies compris-
ing 10 sections per sample group (NMT, grade I, II and III) to examine
the expression levels of selected proteins and phosphoproteins. Impor-
tantly, this was not just another validation set but allowed expansion of
the control cohort. Subsequent to immunostaining, we found EGFR,
pNEK9-T210, NEK9, STAT2, HK2, CKAP4, SET and pAKT1-S473 exhibited
similar patterns of expression across meningioma grades as those seen
by WB (Fig. 6). In the majority of cases, immunostaining was stronger
in meningiomas than in control meninges with relatively little differ-
ence between grades (Fig. 6; Supplementary Table S11). Localisation
of NEK9, STAT2, HK2 and CKAP4 appeared cytoplasmic; SET was
found to be predominantly nuclear, while EGFR was localised to the cy-
toplasm and plasma membrane (Fig. 6). In contrast to the cytoplasmic
immunostaining of NEK9, we observed a strong nuclear presence of
pNEK9-T210 (Fig. 6).
4. Discussion
Meningiomas are the most frequent primary CNS tumours and cur-
rently there is no effective pharmacological therapy.We performedpro-
teomic analyses of frozen meningiomas of all grades compared to
healthymeninges to decipher themolecular signature of these tumours.
In addition to global proteome profiling, we used a dual enrichment ap-
proach; employing affinity chromatography to enrich phosphoproteins
and TiO2 beads to enrich phosphopeptides for a comprehensive analysisFig. 3. Differential protein and phosphoprotein expression between meningioma grades.
meningiomas. Differential expression of proteins is shown: (a) grade II vs. grade I; (b) grade
shown: (d) grade II vs. grade I; (e) grade III vs. grade I and (f) grade III vs. grade II. Depicted
test between replicate measurements). Red dots: Upregulated proteins and phosphoproteins (
proteins (log2 fold change ≤ 1.5; p-value b .05). Grey dots: Proteins and phosphoproteins that d
compared were assigned a fold change of infinity. See also Supplementary Table S8a and b. (g)
(h) Hierarchical clustering of the phosphoprotein molecular signature of grade II and III men
(https://omictools.com/bubblegum-tool). Hierarchical clustering created using Perseus 1.5.0.3
(i) GO enrichment analysis of proteins derived from the molecular signature of GIII meningiom
of GIII meningiomas. GO enrichment analysis was performed using the web tool DAVID v6.
p b .05 and corresponding enrichment for proteins is shown. Gene Ontologies representingMol
in blue. Fold enrichment relative to theH. sapiens proteome is displayed at the x-axis. Proteins a
and f.of the meningioma phosphoproteome. The two datasets shared 56% of
the identified phosphoproteins and several canonical pathways. The
number of phosphoproteins identified by phosphoprotein enrichment
was more than double that identified by phosphopeptide enrichment,
thus we performed in-depth bioinformatics on the phosphoprotein
dataset first to elucidate dysregulated protein activity and biological
functions that underlie meningioma pathogenesis.
Initially, we analysed data by unsupervised hierarchical clustering
based on DEPs across all grades meningioma and NMT as control. For
both global proteome and enriched phosphoproteins, we had a clear
separation of tumours vs. controls, as well as a separation between tu-
mour grades. The only exception was the grade III sample J9, which
was grouped together with grade II tumours; however, since meningio-
mas can progress from a grade II to a grade III, we cannot exclude that
this tumour still retains some grade II features.
We identified 181 proteins and 338 phosphoproteins commonly and
significantly upregulated among all meningioma grades compared to
NMT. Among the commonly upregulated proteins thatwere further val-
idated, we identified both isoforms of the nuclear proto-oncogene SET
(I2PP2A), which participates in many cellular processes including cell-
cycle regulation, gene transcription, epigenetic regulation and cell mi-
gration [46]. SET is overexpressed in other cancers, contributing to
tumourigenesis in part through its inhibition of the tumour suppressor
phosphatase PP2A, which acts as a negative regulator of cellular growth
and survival pathways [46]. Both SET isoforms are components of the
inhibitor of acetyltransferases (INHAT) complex shown to bind his-
tones, predominantly histone H4, and inhibit histone acetyltransferase
activity thus regulating chromatin modification and transcriptional ac-
tivity [47]. Interestingly, histone H4 was another commonly upregu-
lated protein identified by our global proteome analysis. SET is also
part of a complex that localises to the endoplasmic reticulum but was
found in the nucleus inhibiting apoptosis after cytotoxic T lymphocyte
attack [48]. This protein has never been studied in meningioma, but
deciphering the causes of its overexpression and identifying the binding
partners could clarify which role it plays in the pathogenesis and
whether this could lead to a therapeutic intervention.
Another commonly and significantly upregulated protein among all
grades was STAT2, a STAT-family member involved in immune re-
sponse through activation of the JAK/STAT pathway after stimulation
with type I IFNs (IFN-alpha and IFN-beta) [49]. Activated STAT2 forms
heterodimers with STAT1, also found to be commonly upregulated
(Table 1) and previously identified by our group as a common
target in NF2-negative schwannomas and meningioma BM1 cells, and
further validated as overexpressed in meningioma [16] (Ferluga et al.
unpublished). These results, together with the identification of ‘cellular
immune response’ and ‘cytokine signalling’ as two of the most upregu-
lated pathway classes identified by both phosphoprotein and phospho-
peptide enrichment, suggest that the tumour microenviroment and
immunomodulatorymolecules could have a pivotal role inmeningioma
development and progression, and present the STAT protein family as
plausible targets.
In our previous studywe also identified EPS8L2 [16], which herewas
again found commonly overexpressed in allmeningioma grades as both
total and phosphorylated protein. EPS8L2 is a member of the EPS8Volcano plots of protein and phosphoprotein abundance between different grades of
III vs. grade I and (c) grade III vs. grade II. Differential expression of phosphoproteins is
in the plots are the comparisons of log2 fold changes (LFC) versus p-values (Student's t-
log2 fold change ≥ 1.5; p-value b .05). Green dots: Downregulated proteins and phospho-
id not meet these criteria. Proteins and phosphoproteins specific to one of the two groups
Hierarchical clustering of the protein molecular signature of grade II and III meningiomas.
ingiomas. Molecular signatures were generated by the computational tool BubbleGUM
1 software suite. Supplementary Table S9a–d provide details of all molecular signatures.
as. (j) GO enrichment analysis of phosphoproteins derived from the molecular signature
8. Terms containing at least three phosphoproteins with Benjamini-Hochberg adjusted
ecular Function are presented in red, Cellular Component in green and Biological Processes
nd phosphoproteins associatedwith these terms are provided in Supplementary Table S9e
Table 1
Partial list of proteins commonly and significantly upregulated among all grades of meningiomas compared to normal meningeal tissue (log2 fold-change ≥ 1.5; p-value b .05). Proteins
specific to one of the two groups compared were assigned a fold change of infinity.
Gene
symbol
Protein name UniProt Accession
number
Log2 fold-change
(GI vs. NMT)
Log2 fold-change
(GII vs. NMT)
Log2 fold-change
(GIII vs. NMT)
DNJC8 DnaJ homolog subfamily C member 8 O75937 ∞ ∞ ∞
SET Protein SET Q01105 ∞ ∞ ∞
STAT2 Isoform 2 of Signal transducer and activator of transcription 2 P52630-4 ∞ ∞ ∞
ATOX1 Copper transport protein ATOX1 O00244 ∞ ∞ ∞
SON Isoform J of Protein SON P18583-10 ∞ ∞ ∞
TRIP6 Thyroid receptor-interacting protein 6 Q15654 ∞ ∞ ∞
FOXP1 Isoform 2 of Forkhead box protein P1 Q9H334-2 ∞ ∞ ∞
EIF2A Isoform 3 of Eukaryotic translation initiation factor 2A Q9BY44-3 ∞ ∞ ∞
NAV1 Isoform 5 of Neuron navigator 1 Q8NEY1-5 ∞ ∞ ∞
NEK9 Serine/threonine-protein kinase Nek9 Q8TD19 4.83 4.33 2.89
CENPV Isoform 3 of Centromere protein V Q7Z7K6-3 4.57 4.62 4.60
S10AA Protein S100-A10 P60903 4.33 3.66 4.13
SERPH Serpin H1 P50454 4.29 4.43 3.82
ST1A1 Sulfotransferase 1A1 P50225 4.28 4.37 4.09
H4 Histone H4 P62805 4.08 3.17 3.17
SET Isoform 2 of Protein SET Q01105-2 3.74 3.99 4.18
STAT1 Signal transducer and activator of transcription 1-alpha/beta P42224 3.67 3.67 4.46
HDGF Hepatoma-derived growth factor P51858 3.53 3.54 3.53
FLNB Isoform 8 of Filamin-B O75369-8 2.87 2.96 2.67
NUCL Nucleolin P19338 2.85 2.97 3.20
NAMPT Nicotinamide phosphoribosyltransferase P43490 2.78 3.67 3.56
PAXI Isoform Alpha of Paxillin P49023-2 2.65 3.36 2.72
CKAP4 Cytoskeleton-associated protein 4 Q07065 2.63 2.22 2.97
EF1A1 Elongation factor 1-alpha 1 P68104 2.54 2.65 2.41
SRSF1 Serine/arginine-rich splicing factor 1 Q07955 2.12 1.85 1
PAK2 Serine/threonine-protein kinase PAK 2 Q13177 1.99 2.22 2.07
SIAS Sialic acid synthase Q9NR45 1.95 2.32 2.28
SPAG9 Isoform 4 of C-Jun-amino-terminal kinase-interacting protein 4 O60271-4 1.78 2.73 1.74
CLIC1 Chloride intracellular channel protein 1 O00299 1.75 1.90 2.26
EPS8L2 Epidermal growth factor receptor kinase substrate 8-like protein 2 Q9H6S3 1.66 3.26 3.04
Table 2
Partial list of phosphoproteins commonly and significantly upregulated among all grades of meningiomas compared to normal meningeal tissue (log2 fold-change ≥ 1.5; p-value b .05).
Phosphoproteins specific to one of the two groups compared were assigned a fold change of infinity.
Gene
symbol
Protein name UniProt Accession
number
Log2 fold-change
(GI vs. NMT)
Log2 fold-change
(GII vs. NMT)
Log2 fold-change
(GIII vs. NMT)
SSH3 Protein phosphatase Slingshot homolog 3 Q8TE77 ∞ ∞ ∞
ACSS2 Acetyl-coenzyme A synthetase, cytoplasmic Q9NR19 ∞ ∞ ∞
FAK2 Isoform 2 of Protein-tyrosine kinase 2-beta Q14289-2 ∞ ∞ ∞
MRCKB Serine/threonine-protein kinase MRCK beta Q9Y5S2 ∞ ∞ ∞
AKT2 RAC-beta serine/threonine-protein kinase P31751 ∞ ∞ ∞
RPS6KB1 Ribosomal protein S6 kinase beta-1 P23443-4 ∞ ∞ ∞
RTKN Rhotekin Q9BST9 ∞ ∞ ∞
NFKB1 Nuclear factor NF-kappa-B p105 subunit P19838 ∞ ∞ ∞
WASL Neural Wiskott-Aldrich syndrome protein O00401 ∞ ∞ ∞
IRF3 Interferon regulatory factor 3 Q14653 ∞ ∞ ∞
RB1 Retinoblastoma-associated protein P06400 ∞ ∞ ∞
AKT1 RAC-alpha serine/threonine-protein kinase P31749 7.00 5.74 4.97
EPS8L2 Epidermal growth factor receptor kinase substrate 8-like protein 2 Q9H6S3 6.90 5.80 6.14
CTNND1 Isoform 1A of Catenin delta-1 O60716-5 6.72 5.75 5.63
ACACA Acetyl-CoA carboxylase 1 Q13085 5.67 5.84 5.54
TUBB6 Tubulin beta-6 chain Q9BUF5 5.51 4.69 4.31
PRKAA1 Isoform 2 of 5-AMP-activated protein kinase catalytic subunit alpha-1 Q13131-2 4.79 4.11 3.84
S10AA Protein S100-A10 P60903 4.58 5.93 6.88
MAPK2 MAP kinase-activated protein kinase 2 P49137 3.92 1.96 2.64
TUBA1C Tubulin alpha-1C chain Q9BQE3 3.79 2.38 1.89
SRC Proto-oncogene tyrosine-protein kinase Src P12931 3.78 3.63 3.73
FLNB Isoform 2 of Filamin-B O75369-2 3.73 3.17 2.94
PAXI Isoform Alpha of Paxillin P49023-2 3.70 4.26 8.09
FAK1 Isoform 7 of Focal adhesion kinase 1 Q05397-7 3.64 2.00 2.67
MP2K4 Dual specificity mitogen-activated protein kinase kinase 4 P45985 2.66 1.88 1.72
MP2K2 Dual specificity mitogen-activated protein kinase kinase 2 P36507 2.62 2.41 2.05
SET Protein SET Q01105 2.40 3.29 3.18
TUBB4B Tubulin beta-4B chain P68371 2.35 2.44 1.97
PRKDC DNA-dependent protein kinase catalytic subunit P78527 2.14 2.30 2.97
NUCL Nucleolin P19338 1.67 2.22 2.78
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Fig. 4. Compendium of protein phosphorylation sites in meningiomas. (a) Distribution of amino acid phosphorylation for serine, threonine and tyrosine across meningiomas. See
Supplementary Table S10a for all phosphorylation sites. (b) Distribution of phosphorylation site classes in meningiomas. The phosphorylated residue is located at the central position
within a sequence window of 13 amino acids. Classes were defined by the chemical properties of the sequence window peptide as acidic, basic, proline-directed, tyrosine or other by a
binary decision tree method [26]. (c) GO enrichment analysis of 738 phosphoproteins common to the phosphoprotein and phosphopeptide datasets performed by the web tool DAVID
v6.8. Terms containing at least three phosphoproteins with Benjamini-Hochberg adjusted p b .05 are shown. Gene Ontologies representing Molecular Function are presented in red,
Cellular Component in green and Biological Processes in blue. Fold enrichment relative to the H. sapiens proteome is displayed at the x-axis. *positive regulation of basement
membrane assembly = positive regulation of basement membrane assembly involved in embryonic body morphogenesis. Phosphoproteins associated with these terms are provided
in Supplementary Table S10b. (d) Ingenuity Pathway Analysis of commonly upregulated phosphoproteins and proteins associated with identified phosphopeptides. Pathways
significantly associated with two or more phosphoproteins (Fisher's exact test right-tailed, p-value b .05) were grouped into pathway classes according to Ingenuity Canonical Pathways.
Supplementary Tables S7f and S10c provide details of IPA pathway analysis and pathway classification. Grade I n = 3; grade II n = 3 and grade III n = 2.
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still unclear, although it was proposed that they can substitute EPS8
function [50]. High levels of EPS8 were able to induce nuclear transloca-
tion and activation of YAP, a member of the Hippo pathway that is usu-
ally active in NF2-negative meningiomas [51]. EPS8 is also a substrate
for EGFR and it participates in both EGFR signalling through Rac, and ve-
sicular trafficking through Rab5 [52], which is required for the fusion of
plasmamembranes and early endosomes [53]. ‘Cortical actin cytoskele-
ton organization’ and ‘Cytoskeletal anchoring at plasmamembrane’ aretwo GO terms identified in the phosphopeptide dataset, and ‘Transport
vesicle’ is a commonGO term for both total and phosphoproteins, so the
signallingdownstreamEGFR and the role of EPS8L2 inmeningioma cells
certainly warrant further investigation.
One additional validated protein that associates with EGFR and we
find commonly upregulated was CKAP4. This protein is a high-affinity
epithelial cell surface receptor for the antiproliferative factor secreted
by bladder epithelial cells [54] and plays an important role inmediating
the anchoring of the ER to microtubules, but its biological function in
Fig. 5.Western blot validation of proteins and phosphoproteins identified as significantly upregulated inmeningiomas. (a)Western blot analysis of EGFR, pNEK9-T210, NEK9, STAT2, HK2,
EPS8L2, pPXN-Y118, PXN, TRIP6, CKAP4, pAKT2-S474, pAKT-S473, SET, SF2/ASF, S100-A10, ATOX1 across different grades of meningioma and NMT. GAPDHwas used as loading control.
Clinical details of the validation set used in this figure are presented in Supplementary Table S2. (b) Histogram representing Western blot quantification of EGFR, NEK9, STAT2, HK2,
EPS8L2, PXN, TRIP6, CKAP4, AKT2, AKT1, SET, SF2/ASF, S100-A10 and ATOX1 shown in (a) compared to levels in NMT. Statistical significance is shown by: *p ≤ .05; **p ≤ .01; ***p
≤ .001; NS: not significant. NMT n = 3; grade I n = 5, grade II n = 5 and grade III n = 5.
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ling’ and ‘positive regulation of microtubule polymerization’ GO terms
and its role should be further deciphered.
Comparing our global proteome dataset with the previously gener-
ated proteomes by Sharma et al. [13], who similarly analysed all menin-
gioma grades, we identified an overlap of 1428proteins. Amongour 181
upregulated DEPs common to all grades, 25 were also found by Sharma
et al., including validated proteins like CKAP4 and S100-A10. Further,
we identified MX1, ANP32E, SUPT16H, NEK9 and DDX42 as commonly
upregulated among all grades, which were previously shown by
Saydam et al. to be expressed in a human benign meningioma cell line
vs. human primary arachnoidal cells [32].
Among the phosphoproteins that were commonly and significantly
upregulated in all grades compared to NMT we identified phosphopro-
teins that are well characterised in cancer like phopsho-RB1, phospho-
SRC or phospho-FAK, and others that are novel. Validation studies on
phosphoproteins are more challenging as they rely on availability of
phospho-specific antibodies. Here, we validated the overexpression
and activation of PXN across all grades that works as a scaffold at the
focal adhesions sites interacting with structural and signalling proteins
like FAK and SRC. Following phosphorylation in response to growth fac-
tors and integrin-mediated cell adhesion, phospho-PXN regulates cell
proliferation, adhesion and motility [55]. Further to identification of
the enriched GO term ‘focal adhesion’, we observed phospho-PXN wasexpressed in two-thirds of the meningiomas analysed but not in NMT,
so the therapeutic potential of targeting this signalling should be further
investigated.
One additional validated protein, which was significantly
overexpressed and phosphorylated across all grades but not in NMT
wasNEK9, a serine/threonine-protein kinase of theNIMA family protein
kinases that together with other members of the family functions in the
regulation of mitosis [56]. In particular, NEK9 controls G1/S transition
and S phase progression when phosphorylated on T210 and associated
with the heterodimeric complex FACT, formed by the proteins SPT16
and SSRP1 [57]; indeed, both proteins were also identified in our prote-
ome dataset as upregulated in all grades compared to NMT, like the val-
idated phospho-NEK9. Although NEK9 has been previously identified to
be exclusively expressed in a benign meningioma cell line compared to
primary arachnoidal cells, its phosphorylated active form has not been
shown in meningioma until now [32]. Furthermore, NEK9 activates
the family members NEK6 and NEK7, and together the three proteins
function in mitotic progression with a role in mitotic spindle formation,
a GO term established as enriched among phosphoproteins identified as
commonly upregulated among all grades in our dataset [58]. Phosphor-
ylated NEK7 was also identified as commonly overexpressed in all
grades compared to NMT and detected in our phosphopeptide analysis
to be phosphorylated on S195, the phosphorylation of which is
catalysed by NEK9 [58]. Recent studies have identified NEK9 as a potent
Fig. 6. Immunohistochemistry validation of proteins and phosphoproteins identified as significantly upregulated inmeningiomas. Representative images showing immunohistochemical
staining of EGFR, pNEK9-T210, NEK9, STAT2, HK2, CKAP4, SET and pAKT-S473 in all meningioma grades compared to NMT (see black arrow for normal meninges). Mean intensity scores
are presented below for meningioma specimens and normal meninges examined. Supplementary Table S11 details the full list of specimens and corresponding semi-quantitative
assessment. NMT n = 10; grade I n = 10, grade II n = 10 and grade III n = 10.
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growth of NRAS- and KRAS-mutant cancer cells [59]. Our findings thus
present NEK9, as well as NEK7 and the FACT complex as potential
novel drug targets in meningioma, proposing their further validation.
In addition to identifying common molecular signatures between
grades, we wanted to characterise signatures specific to grade II and III
as these tumours are more therapeutically challenging. Among the 191
proteinsdefiningagrade II signaturewe foundmucin-4 (MUC4), its over-
expression enhanced proliferation and invasive potential of GBM cells by
upregulating EGFR expression [60]; indeed, silencing EGFR in pancreatic
cancer cells decreased MUC4 expression by reducing the phosphoryla-
tion of STAT1 [61]. Within the grade III-specific proteins we identified
the glycolytic enzyme HK2, known for its key role in aerobic glycolysis
and thus, the “Warburg effect” in rapidly growing cancer cells [33]. HK2
has previously been associated with the promotion of tumour growth,migration and metastasis in GBM and pancreatic cancer [62,63]. HK2
was further validated, demonstrating significantly higher expression in
grade II and III meningiomas compared to NMT and grade I as well as
clearly displaying a much stronger immunoreactivity in IHC in grade III
meningiomas. Indeed, the inhibition of HK2 in cancer by administration
of small-molecule inhibitors such as 3-bromopyruvate and the develop-
ment of selective HK2 inhibitors indicate the potential of targeting this
enzyme in high-grade meningioma [64,65].
We also validated expression and activation of AKT1 and AKT2 as
possible therapeutic targets. Clark et al. described a constitutively active
mutation of AKT1 (AKT1E17K) in NF2-positive meningiomas [5], and
other studies have shown that inhibition of phospho-AKT1 by the
Integrin-Linked Kinase inhibitor OSU-T315 in BM1 cells was able to ar-
rest cell cycle and induce cell death [66]. Further, expression of AKT2 in
meningiomawas previously described as a potential prognostic marker
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in all grades, and pAKT1-S473 was persistently identified in grade I and
II. We conducted preliminary functional validation experiments as
proof of principle to determine if the inhibition of pAKT1-S473 was a
more effective therapeutic target in low rather than high-grade menin-
gioma. However, we observed AKT inhibition did not produce a strong
reduction in cell viability independent of grade. Instead, we demon-
strated inhibition with a dual mTOR inhibitor may prove to have in-
creased efficacy in lower, compared to higher-grade meningioma. An
additional possibility for aberrant AKT1 activation in meningioma
could be CKAP4, a protein also identified as consistently overexpressed
in grade I and II meningiomas in our data, where pAKT1wasmainly de-
tected. Recent studies of pancreatic and lung cancers have related the
activation of AKT1 to CKAP4 and its binding to the secretory protein
Dickkopf1, leading to the downstream activation of PI3K and enhanced
cellular proliferation [68].
Interestingly, our data highlighted an enrichment of GO terms re-
lated to RNA metabolism such as RNA helicase activity and splicing,
not yet described inmeningioma.We repeatedly identifiedmanymem-
bers of the DEAD-box family of RNA helicases by both global proteome
and phosphoprotein analysis including DDX5, DDX6, DDX10, DDX17,
DDX19B DDX24, DDX39A and DDX42 to be significantly upregulated
in one or more grades of meningioma compared to NMT. Furthermore,
we identified several components of the spliceosome as upregulated in
meningioma including SNRPD3, SNRPF, SNRPE, SF3B2, SF3B5 as well as
the splicing factors SRSF3, SRSF7 and SF2/ASF, the latter of which we
validated as overexpressed in meningioma compared to NMT. Upregu-
lation of SF2/ASF has been shown inmany different human cancers and
its overexpression causes oncogenic transformation of immortal rodent
fibroblasts that can form sarcomas in nudemice [69]. SF2/ASFmay con-
tribute to tumourigenesis through aberrant splicing of its target genes
including the tumour suppressor BIN1, identified as downregulated in
our analysis of grade II vs. grade I meningioma. Aberrant splicing by
SF2/ASF promotes an alternative BIN1 isoform lacking its tumour sup-
pressive pro-apoptotic function [69]. Taken together, these results pro-
pose further investigation into RNA metabolism in meningioma may
reveal targetable pathways and protein families, in addition to increas-
ing our knowledge of the underlying molecular pathogenesis of these
tumours.
In summary, we performed a comprehensive analysis of proteins
and phosphoproteins in meningioma tissue of all grades compared to
healthymeninges.We identifiedmany relevant differentially expressed
and aberrantly phosphorylated proteins common to all or grade-
enriched. We validated a panel of candidates that following further
studies incorporating different tumours may be potential biomarkers
for all grades, like SET, STAT2, NEK9 and pNEK9, AKT1 and AKT2; and
proteins/phosphoproteins enriched in grade I-II, like ATOX1, CKAP4
and pAKT1 or in grade III like HK2. Finally, we discussed pathways
that appear to have a pivotal role in meningioma pathogenesis, like
RNA metabolism, EGFR signalling, integrin-mediated cellular adhesion
and cellular immune response.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2018.12.048.
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